July is Sarcoma Awareness Month and according to Cleveland Clinic, sarcoma accounts for about 1 percent of adult cancers but 15 percent to 20 percent of childhood cancers. The Black community speaks ...
Zacks Investment Research on MSN
SMMT shares updated Ivonescimab survival data from NSCLC study
Summit Therapeutics SMMT announced updated overall survival ("OS") data from the phase III HARMONi study evaluating its investigational antibody ivonescimab in certain patients with non-small cell ...
Summit Therapeutics has released more Phase III trial data for ivonescimab in non-small cell lung cancer (NSCLC) as it awaits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results